论文部分内容阅读
目的探讨肾癌中p16蛋白与PCNA的表达与肾癌组织学类型、临床分期、病理分级及预后的关系。方法采用免疫组织化学SP法检测41例肾癌及18例癌旁正常肾组织中p16蛋白及PC－NA的表达。结果p16蛋白在肾癌及癌旁正常肾组织中的阳性表达率间具有显著性差异（P＜0.05），p16蛋白表达在肾透明细胞癌及颗粒细胞癌间无显著性差异，随肾癌分级、分期升高而明显降低，p16阳性表达组术后5年生存率明显高于阴性表达组；肾癌及癌旁肾组织中PCNA的阳性表达率增高，与预后有关，与肾癌的组织类型及分期无关。结论p16基因及蛋白的检测可作为肾癌的辅助诊断及预后判断的参考指标；PCNA可作为肿瘤恶性程度的判断及预后的参考指标。
Objective To investigate the relationship between the expression of p16 protein and PCNA and the histological type, clinical stage, pathological grade and prognosis of renal cell carcinoma. Methods Immunohistochemical SP method was used to detect the expression of p16 protein and PC-NA in 41 cases of renal cell carcinoma and 18 cases of adjacent normal tissues. Results The positive expression rate of p16 protein in renal cell carcinoma and adjacent normal renal tissue was significantly different (P <0.05). There was no significant difference in p16 protein expression between renal clear cell carcinoma and granulosa cell carcinoma, , Staging increased significantly reduced the p16 positive expression group 5-year survival rate was significantly higher than the negative expression group; renal cell carcinoma and paracancer tissue PCNA positive expression rate increased, and prognosis, and renal cell carcinoma tissue type And the stage has nothing to do. Conclusion The detection of p16 gene and protein can be used as a reference index for adjuvant diagnosis and prognosis of renal cell carcinoma. PCNA can be used as a reference to judge malignant degree and prognosis of renal cell carcinoma.